<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038545</url>
  </required_header>
  <id_info>
    <org_study_id>DM01-008</org_study_id>
    <nct_id>NCT00038545</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Patients With Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">25</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim SD/01</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:

          -  Bidimensionally measurable current/refractory aggressive NHL (Diffuse lg cell, diffuse
             mixed cell, follicular lg non-cleaved, immunoblastic, Ki-1+ALCL, peripheral T-cell
             lymphoma, mantle cell lymphoma &amp; transformed lymphoma.)

          -  No more than 3 prior treatment regimens. No anti-lymphoma therapy within the past 3
             weeks.

          -  Not be eligible for treatment of a higher priority.

          -  Performance status &lt;2 Zubrod, &gt; 60 Karnofsky.

          -  Good marrow reserve: ANC&gt;1.5 x 10(9)/L, platelets &gt; 100 x 10(9)/L.

          -  Bilirubin &lt;1.5mg/dL, SGOT, SGPT &lt; 2 x normal values.

          -  Serum creatinine &lt; 1.8 mg/dL.

          -  Age &gt; 18 yrs.

          -  Signed informed consent.

          -  Life expectancy of &gt; 12 weeks.

          -  No prior Taxane (paclitaxel or docetaxel), topotecan, or CPT-11.

          -  No prior stem cell or bone marrow transplantation.

          -  No prior second malignancies except for basal cell carcinoma of the skin.

        EXCLUSION:

          -  Active or prior history of CNS lymphoma.

          -  Serious intercurrent medical illnesses requiring hospitalization.

          -  History of primary/secondary immunodeficiency (other than related to the malignant
             lymphoma because treatment is dependent on a functional immune system) or patients
             taking immunosuppressive drugs (systemic corticosteroids).

          -  Prior exposure to Filgrastim-SD/01.

          -  Women who are pregnant or lactating.

          -  Participation in another clinical trial.

          -  Positive HIV antibody.

          -  History of prior sensitivity to E. coli derived products (such as
             filgrastim/neupogen).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anas Younes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2002</study_first_submitted>
  <study_first_submitted_qc>May 31, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2002</study_first_posted>
  <last_update_submitted>January 20, 2012</last_update_submitted>
  <last_update_submitted_qc>January 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LYMPHOMA</keyword>
  <keyword>NON-HODGKINS</keyword>
  <keyword>AGGRESSIVE</keyword>
  <keyword>RELAPSED AND REFRACTORY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

